TrialBlood2022

Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study.

Yuqin Song et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.